All In Biotech

Drug Trial Radar · NCT02595073

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Atopic Dermatitis.

Last checked: Nov 20, 2026Latest source record: Dec 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Sep 4, 2015

Primary completion

Jan 17, 2017

Study completion Aug 29, 2017

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis

Conditions

  • Atopic Dermatitis

Interventions

  • DSXSDrug

    Active treatment

  • PlaceboDrug

    Placebo treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Patients in Each Treatment Group That Have Clinical SuccessTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taro Pharmaceuticals USA Inc.

    Hawthorne, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.